Retatrutide (20mg)

Retatrutide is a synthetic peptide that acts as a triple agonist at the GLP-1, GIP, and glucagon receptors simultaneously. This tri-receptor activity profile is what separates it from earlier compounds like semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP), and is the basis for the significant fat loss results observed in Phase 2 clinical trials.

The 20mg vial is the right call if you've already done a first run and know you want to continue. You get twice the compound for less than twice the price — better value per milligram, fewer reconstitution cycles, and no risk of running short mid-protocol. The compound, purity standard, and CoA verification are identical to the 10mg format. Think of the 10mg as the entry point and the 20mg as the commitment.

In the research community, Retatrutide is commonly referred to as Reta peptide or simply Reta. It is also sometimes searched for as Reda peptide or Retatrude — both common misspellings. The shorthand r3ta peptide (using a numeral 3) also appears frequently in online research communities. One particularly common autocorrect error is 'ratatouille peptide' — if that's what brought you here, you're in the right place.

Phase 2 clinical trials observed mean body weight reductions of up to 24% over 48 weeks — significantly outperforming semaglutide and tirzepatide in head-to-head comparisons. Subjects showed dramatic reductions in waist circumference, visceral fat, and improvements across cardiometabolic markers including blood pressure and LDL cholesterol. The appetite suppression was described as profound, with energy intake reductions sustained throughout the full trial period.

Retatrutide hits three separate pathways at once: GLP-1 receptors suppress appetite and slow digestion; GIP receptors improve insulin sensitivity and amplify fat loss; glucagon receptors increase energy expenditure by driving the liver to burn more fuel. Most weight loss compounds only target one or two of these. Retatrutide targets all three simultaneously — which is why the Phase 2 results were so far ahead of semaglutide and tirzepatide.

Semaglutide (Ozempic/Wegovy) targets one receptor — GLP-1. Tirzepatide (Mounjaro) targets two — GLP-1 and GIP. Retatrutide targets three — GLP-1, GIP, and glucagon. In Phase 2 trials, Retatrutide produced a mean 24% body weight reduction over 48 weeks. Tirzepatide achieved around 20% in comparable studies, semaglutide around 14–15%. The glucagon component — which drives energy expenditure directly — is the key differentiator.

Retatrutide is supplied as a lyophilized powder and should be reconstituted with bacteriostatic water (BAC water) immediately before use. Inject the BAC water slowly into the vial, directing the stream down the inside wall. Gently swirl to dissolve — do not shake. Once reconstituted, store at 2–8°C and use within 28 days. For a full step-by-step walkthrough, see our complete peptide reconstitution guide.

Store lyophilized Retatrutide vials at -20°C, away from light and moisture. After reconstitution, refrigerate at 2–8°C and use within 28 days. Do not freeze reconstituted solution.

Retatrutide (20mg) is available through Aussie Peptides with fast domestic shipping to all Australian states and territories. Every vial is dispatched from within Australia — no customs delays, no international freight uncertainty. Each batch undergoes third-party analysis and the Certificate of Analysis is available to view in our CoA library.